Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Genetic Technologies stock price, quote, forecast and news

GTG.AX
AU000000GTG7
893882

Price

0.04
Today +/-
+0.00
Today %
+4.88 %
P

Genetic Technologies stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Genetic Technologies stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Genetic Technologies stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Genetic Technologies stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Genetic Technologies's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Genetic Technologies Stock Price History

DateGenetic Technologies Price
9/6/20240.04 undefined
9/5/20240.04 undefined
9/4/20240.04 undefined
9/3/20240.04 undefined
9/2/20240.04 undefined
8/29/20240.04 undefined
8/28/20240.04 undefined
8/27/20240.04 undefined
8/26/20240.05 undefined
8/23/20240.05 undefined
8/22/20240.04 undefined
8/21/20240.04 undefined
8/20/20240.04 undefined
8/19/20240.04 undefined
8/16/20240.04 undefined
8/15/20240.04 undefined
8/14/20240.04 undefined
8/13/20240.04 undefined
8/12/20240.04 undefined
8/9/20240.04 undefined

Genetic Technologies Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Genetic Technologies, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Genetic Technologies from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Genetic Technologies’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Genetic Technologies. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Genetic Technologies’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Genetic Technologies’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Genetic Technologies’s growth potential.

Genetic Technologies Revenue, EBIT and net profit per share

DateGenetic Technologies RevenueGenetic Technologies EBITGenetic Technologies Net Income
20238.69 M undefined-10.19 M undefined-11.75 M undefined
20226.79 M undefined-7.57 M undefined-7.13 M undefined
2021120,550 undefined-7.69 M undefined-7.08 M undefined
20209,860 undefined-6.54 M undefined-6.29 M undefined
201925,440 undefined-6 M undefined-6.43 M undefined
2018189,250 undefined-6.11 M undefined-5.46 M undefined
2017518,510 undefined-7.74 M undefined-8.4 M undefined
2016824,590 undefined-8.5 M undefined-8.46 M undefined
20152.01 M undefined-9.54 M undefined-8.81 M undefined
20144.56 M undefined-9.81 M undefined-10.13 M undefined
20133.38 M undefined-9.14 M undefined-9.3 M undefined
20123.69 M undefined-11.01 M undefined-5.29 M undefined
20114.59 M undefined1.05 M undefined910,000 undefined
20109.97 M undefined-7.47 M undefined-9.34 M undefined
200912.18 M undefined-7.5 M undefined-7.84 M undefined
200815.98 M undefined-2.75 M undefined-5.45 M undefined
200715.32 M undefined-2.62 M undefined-4.33 M undefined
200610.76 M undefined-7.7 M undefined-7.92 M undefined
200510.85 M undefined-9.45 M undefined-10.47 M undefined
20045.42 M undefined-9.52 M undefined-10.71 M undefined

Genetic Technologies Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (B)DOCUMENTS
19981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
00451395101015151294334200000068
---25.00160.00-30.77-44.44100.00-50.00--20.00-25.00-55.56-25.00-33.33-50.00-------33.33
-----77.7840.0090.0080.0086.6793.3375.0077.7850.0033.3333.3350.0050.00------50.0050.00
0000072981314972112100000034
000-33-2-9-9-7-2-2-7-71-11-9-9-9-8-7-6-5-6-7-7-10
----60.0023.08-22.22-180.00-90.00-70.00-13.33-13.33-58.33-77.7825.00-366.67-300.00-225.00-450.00-------116.67-125.00
-3-2-2-3-8-4-10-10-7-4-5-7-90-5-9-10-8-8-8-5-6-6-7-7-11
--33.33-50.00166.67-50.00150.00--30.00-42.8625.0040.0028.57--80.0011.11-20.00---37.5020.00-16.67-57.14
0.110.110.120.230.280.280.290.340.390.390.390.40.410.430.490.510.621.151.842.272.612.824.160.090.10.11
--------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Genetic Technologies Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Genetic Technologies is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (k)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (k)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (k)DEFERRED TAXES (k)OTHER LIAB. (k)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
19981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                   
6.124.925.43.28.016.1411.418.4111.8913.3312.927.832.965.038.921.930011.1810.995.492.1314.2120.911.737.85
0000.060.221.230.910.571.40.651.61.790.730.660.440.3000.390.20.010.020.791.070.440.19
0000.030.010.010.030.130000.040.020.010.060.03000.240.230.290.8001.981.73
203000000000030026028032021000166.9476.8259.0131.8791.3976.93398.15325.89
0000.090000.580.680.621.380.140.530.270.220.180.200.150.140.140.210.10.180.170.4
6.144.955.43.388.247.3812.3419.6913.9714.615.910.14.56.259.962.650.2012.1311.635.993.215.1922.2414.7210.5
0.350.480.330.80.491.491.852.612.271.951.73.011.980.950.640.42000.550.480.180.070.440.640.950.6
0.2302.028.140.280.750.7300000004.413.930.8000000000
000000000000000000000000.991.981.73
0002.8523.5820.223.5520.0516.4611.95.983.031.481.41.121.310.8600.61000000.620.52
00024.510.410.440.410.390.320.320.321.580.320.320.3200.3200000004.513.12
6.514.371.0900000.740.720.690.210.26000000000000.100.12
7.094.853.4436.324.7622.8826.5423.7919.7714.868.217.883.782.676.495.661.9701.160.480.180.070.441.728.066.09
13.239.88.8439.683330.2638.8843.4833.7429.4624.1117.988.288.9216.458.312.18013.2912.116.173.2715.6323.9622.7816.59
                                                   
19.7119.7120.2153.9639.3539.6857.0870.2470.2470.2470.2471.2972.3872.3883.2883.7400115.27122.38122.37125.5140.11153.57155.14161.34
1.561.561.561.560000000000000000000000
-8.18-12.07-14.35-17.55-8.24-12.29-22.97-33.44-40.18-44.29-49.6-57.33-66.84-65.61-68.87-77.9500-104.81-113.09-118.43-124.52-126.12-132.04-139.45-151.03
0000000000000-0.16-0.16-0.15001.421.290.770.79000.750.85
00000000000000000000000000
13.099.27.4237.9731.1127.3934.1136.830.0625.9520.6413.965.546.6114.255.640011.8810.584.711.7713.9921.5316.4311.16
0.030.050.390.450.721.982.52.580.910.851.291.620.680.650.330.62000.390.40.540.590.720.761.150.84
000.250.340.180.250.721.390.71.030.950.990.990.840.971.14000.670.870.690.830.4301.471.07
0.10.010.640.020.270.040.740.50.850.890.690.790.420.460.610.7000.270.20.220.0700.470.921.1
0008207007007000000038070000000000000
000000044049048011037000200000000240.92179.63264.13303.57
0.130.061.281.631.872.974.664.912.953.253.043.772.472.021.932.46001.331.471.451.491.41.413.813.31
00000009104905019000000000000240.8724.41388.4229.28
000000000000000000000000148.01121.9
00000007004050809080801101000074.3163.963.390.811.938.8622.530.44
00000001.610.530.10.270.090.080.080.110.1000.070.06000.240.030.560.38
0.130.061.281.631.872.974.666.523.483.353.313.862.552.12.042.56001.411.531.451.491.641.444.373.69
13.229.268.739.632.9830.3638.7743.3233.5429.323.9517.828.098.7116.298.20013.2912.116.173.2715.6322.9720.814.86
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Genetic Technologies provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Genetic Technologies's financial health and stability.

Assets

Genetic Technologies's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Genetic Technologies must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Genetic Technologies after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Genetic Technologies's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (k)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
19981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0000000000000000000000-6-7-7-11
00000000000000000000000000
00000000000000000000000000
00000011101100000000001121
00000000000000000000000001,000
00000000000000000000000000
0000000000000000000000-1-1-2-1
000-2-30-5-5-520-4-42-7-7-10-9-7-6-5-6-5-6-5-9
00000000000000000000000000
-2-10190000000-100001000000-30
-2-10190000000000002000000-30
00000000000000000000000000
00000000000000005200000000
00000010130000101007230803211507
000000101200000010011220703181305
------------------2.00-----3.00-1.00--
00000000000000000000000000
-3-20-32-2-10-143-1-11-83-4-14-95-14-7-11-950-17-15
-0.55-0.53-0.32-2.36-3.51-1.19-6.08-6.41-6.122.440.3-5.13-4.692.09-7.75-7.57-11.04-9.88-8.03-7.05-5.64-6.12-5.75-7.04-5.76-9.74
00000000000000000000000000

Genetic Technologies stock margins

The Genetic Technologies margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Genetic Technologies. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Genetic Technologies.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Genetic Technologies's sales revenue. A higher gross margin percentage indicates that the Genetic Technologies retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Genetic Technologies's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Genetic Technologies's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Genetic Technologies's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Genetic Technologies. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Genetic Technologies's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Genetic Technologies Margin History

Genetic Technologies Gross marginGenetic Technologies Profit marginGenetic Technologies EBIT marginGenetic Technologies Profit margin
202350.09 %-117.37 %-135.28 %
202255.65 %-111.41 %-104.95 %
2021-41.4 %-6,375.55 %-5,871.11 %
2020-928.7 %-66,281.54 %-63,841.58 %
2019-985.97 %-23,577.44 %-25,257.86 %
2018-58.57 %-3,226.25 %-2,887.12 %
20175.03 %-1,493.17 %-1,620.77 %
20169.89 %-1,031.34 %-1,025.84 %
201555.7 %-474.16 %-437.9 %
201459.87 %-215.13 %-222.15 %
201342.31 %-270.41 %-275.15 %
201247.15 %-298.37 %-143.36 %
201155.77 %22.88 %19.83 %
201072.72 %-74.92 %-93.68 %
200975.78 %-61.58 %-64.37 %
200889.99 %-17.21 %-34.11 %
200787.01 %-17.1 %-28.26 %
200681.32 %-71.56 %-73.61 %
200584.42 %-87.1 %-96.5 %
200452.03 %-175.65 %-197.6 %

Genetic Technologies Stock Sales Revenue, EBIT, Earnings per Share

The Genetic Technologies earnings per share therefore indicates how much revenue Genetic Technologies has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Genetic Technologies earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Genetic Technologies's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Genetic Technologies’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Genetic Technologies's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Genetic Technologies Revenue, EBIT and net profit per share

DateGenetic Technologies Sales per ShareGenetic Technologies EBIT per shareGenetic Technologies Earnings per Share
20230.08 undefined-0.1 undefined-0.11 undefined
20220.07 undefined-0.08 undefined-0.07 undefined
20210 undefined-0.09 undefined-0.08 undefined
20200 undefined-0 undefined-0 undefined
20190 undefined-0 undefined-0 undefined
20180 undefined-0 undefined-0 undefined
20170 undefined-0 undefined-0 undefined
20160 undefined-0 undefined-0 undefined
20150 undefined-0.01 undefined-0.01 undefined
20140.01 undefined-0.02 undefined-0.02 undefined
20130.01 undefined-0.02 undefined-0.02 undefined
20120.01 undefined-0.02 undefined-0.01 undefined
20110.01 undefined0 undefined0 undefined
20100.02 undefined-0.02 undefined-0.02 undefined
20090.03 undefined-0.02 undefined-0.02 undefined
20080.04 undefined-0.01 undefined-0.01 undefined
20070.04 undefined-0.01 undefined-0.01 undefined
20060.03 undefined-0.02 undefined-0.02 undefined
20050.03 undefined-0.03 undefined-0.03 undefined
20040.02 undefined-0.03 undefined-0.04 undefined

Genetic Technologies business model

Genetic Technologies Ltd is an Australian biotechnology company that was founded in 1989. The company is an internationally recognized provider of genomic analysis procedures and technologies and has been operating in various business sectors since its establishment. Genetic Technologies is headquartered in Melbourne, Australia, and maintains offices in the USA, Europe, and Asia. The company's business model is based on the development and commercialization of genetic analysis systems and technologies. Genetic Technologies serves a wide range of customers, including research institutes, universities, diagnostic laboratories, biotechnology companies, and pharmaceutical companies. The company specializes in the analysis of DNA sequences and offers various genetic testing procedures to, for example, identify genetic risk factors for certain diseases or determine the ancestry of individuals. Genetic Technologies' different business sectors include clinical diagnostics, agriculture, forensic science, and scientific research. The company develops and markets various genetic testing procedures, such as the BREVAGenplus test, which aims to help women determine their risk for breast and ovarian cancer. Genetic Technologies also plays a leading role in agriculture, offering, for example, the CalfStart test, which allows breeders to determine the genetic potential of their calves. In forensic science, Genetic Technologies develops DNA tests that help solve criminal cases and identify perpetrators. Furthermore, the company also provides genetic counseling services. Another important area of Genetic Technologies is the development and commercialization of genetic analysis procedures and technologies. The company holds several patents worldwide for DNA analysis procedures, including the patented non-coding procedure, which represented a significant breakthrough in genomic research. Genetic Technologies' chairman, Dr. Mervyn Jacobson, is a recognized expert in the field of genomic research and has already authored numerous scientific publications on this topic. In addition to its various business sectors and products, Genetic Technologies has also established close relationships with other companies and institutions in the biotechnology industry. For example, the company collaborates closely with the USA-based HudsonAlpha Institute for Biotechnology to jointly develop innovative DNA technologies and procedures. Overall, Genetic Technologies has made a name for itself as a company specializing in the analysis of DNA sequences. Through its innovative products and services, the company has contributed to advancing genomic research and gaining new insights into the genetic basis of diseases and other phenomena. With its broad range of business sectors and international presence, Genetic Technologies is an important player in the biotechnology industry and is likely to further expand in the coming years. Genetic Technologies is one of the most popular companies on Eulerpool.com.

Genetic Technologies SWOT Analysis

Strengths

Genetic Technologies Ltd has a strong portfolio of intellectual property rights and patents in the field of genetic testing and analysis. The company's proprietary technologies and algorithms provide a competitive advantage.

The company has established strong partnerships and collaborations with leading research institutions and pharmaceutical companies, enhancing its reputation and access to valuable resources and expertise.

Genetic Technologies Ltd has a diverse and experienced team of scientists, researchers, and professionals who contribute to the company's innovation and success in developing advanced genetic tests and solutions.

Weaknesses

The company heavily relies on a limited number of key partnerships for the commercialization of its products and services. Any disruption or termination of these partnerships could adversely affect Genetic Technologies Ltd's revenue and growth prospects.

Genetic Technologies Ltd faces significant competition from both established players and emerging companies in the genetic testing industry. This intense competition may impact the company's market share and pricing power.

The company's financial performance has been inconsistent, with periods of losses and negative cash flows. This may limit its ability to invest in research and development and hinder the company's growth potential.

Opportunities

The growing demand for personalized medicine and advancements in genomic research present significant opportunities for Genetic Technologies Ltd. The company can leverage its expertise and technology to develop new genetic tests and personalized treatment solutions.

Expansion into new geographic markets, particularly emerging economies, can be an attractive opportunity for Genetic Technologies Ltd to tap into untapped customer bases and increase its market reach.

Strategic partnerships with healthcare providers and payers can help Genetic Technologies Ltd in expanding access to its genetic tests and services, while also ensuring reimbursement and insurance coverage for patients.

Threats

Changing regulations and legal challenges related to genetic testing and data privacy can pose significant threats to Genetic Technologies Ltd's operations. Compliance with evolving regulatory frameworks requires continuous investment and attention.

Rapid technological advancements and new entrants in the genetic testing industry can lead to disruptions and make it crucial for Genetic Technologies Ltd to stay at the forefront of innovation to maintain its competitive position.

Economic downturns and uncertainties can impact consumer spending on discretionary services, which may include genetic testing. Genetic Technologies Ltd needs to be prepared to navigate potential market fluctuations and maintain its customer base.

Genetic Technologies Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Genetic Technologies historical P/E ratio, EBIT, and P/S ratio.

Genetic Technologies shares outstanding

The number of shares was Genetic Technologies in 2023 — This indicates how many shares 106.091 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Genetic Technologies earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Genetic Technologies's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Genetic Technologies’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Genetic Technologies's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Genetic Technologies Stock splits

In Genetic Technologies's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Genetic Technologies.

Genetic Technologies latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2014-0.28 -0.01  (98.02 %)2014 Q4
1

Genetic Technologies list of shareholders

%
Name
Stocks
Change
Date
1.53 % Rubenstein (Peter Irwin)3,698,530617,2093/6/2024
0.93 % Muchnicki (Jerzy)2,246,860112/18/2023
0.90 % Wright (Warwick)2,175,0001,763,5728/21/2023
0.60 % Doma 193 Pty. Ltd.1,445,51408/21/2023
0.20 % AP 300 Pty. Ltd.480,400255,4008/21/2023
0.17 % Monument Hill Pty. Ltd.420,000-338,4938/21/2023
0.17 % Spiteri (Susan)401,428-78,9728/21/2023
0.17 % Kamer (Helen)400,000400,0008/21/2023
0.16 % Tao (Lei Da)380,000380,0008/21/2023
0.13 % Aquasafe Investments Pty. Ltd.306,08027,6368/21/2023
1
2
3

Genetic Technologies Executives and Management Board

Mr. Simon Morriss
Genetic Technologies Chief Executive Officer
Compensation 628,670
Mr. Kevin Camilleri
Genetic Technologies Chief Executive Officer - EasyDNA
Compensation 254,584
Mr. Carl Stubbings
Genetic Technologies Chief Commercial Officer
Compensation 250,593
Dr. Richard Allman57
Genetic Technologies Chief Scientific Officer
Compensation 224,645
Mr. Peter Rubinstein
Genetic Technologies Non-Executive Independent Chairman of the Board
Compensation 169,593
1
2

Most common questions regarding Genetic Technologies

What values and corporate philosophy does Genetic Technologies represent?

Genetic Technologies Ltd represents a commitment to genetic research and innovation in the field of personalized medicine. The company's core values include integrity, scientific excellence, and a strong focus on patient care. With a vision to enhance healthcare outcomes through genetic testing, Genetic Technologies aims to provide cutting-edge solutions to assist healthcare providers and empower individuals in making informed decisions about their health. By leveraging advanced technologies and partnerships, Genetic Technologies demonstrates a corporate philosophy centered on driving advancements in genomics and improving the quality of global healthcare.

In which countries and regions is Genetic Technologies primarily present?

Genetic Technologies Ltd is primarily present in Australia, where it is headquartered. The company operates in multiple regions within Australia, including Victoria and Queensland. As a global provider of molecular risk assessment tools, Genetic Technologies also has a presence in the United States. With an aim to improve healthcare through innovative genetic testing solutions, Genetic Technologies Ltd continues to expand its reach and strive for advancements in the field of genomics.

What significant milestones has the company Genetic Technologies achieved?

Genetic Technologies Ltd, a leading biotechnology company, has achieved numerous significant milestones throughout its journey. The company has successfully developed innovative genetic testing solutions, positioning itself as a pioneer in the field. Genetic Technologies Ltd has gained recognition for its breakthrough research and development, resulting in the development of commercially viable products. Additionally, the company has formed strategic partnerships, expanding its reach and enhancing its market presence. With its dedication to advancing genetic technologies, Genetic Technologies Ltd has secured valuable patents and intellectual property rights, further solidifying its position as a key player in the industry. Overall, Genetic Technologies Ltd has a proven track record of accomplishments, making it a compelling choice for investors seeking growth opportunities in the biotech sector.

What is the history and background of the company Genetic Technologies?

Genetic Technologies Ltd is a renowned biotechnology company specializing in genetic testing and analysis. Established in 1989, the company has a rich history of over three decades in the field. Genetic Technologies has emerged as a leader in developing and commercializing innovative gene-based solutions for various industries, including healthcare, agriculture, and forensic sciences. With a strong focus on genetic research, the company has garnered international recognition for its expertise in DNA analysis, genotyping, and molecular diagnostics. Genetic Technologies Ltd continues to pioneer advancements in genetic science, empowering individuals and businesses with valuable genetic insights and solutions.

Who are the main competitors of Genetic Technologies in the market?

The main competitors of Genetic Technologies Ltd in the market include companies such as Myriad Genetics Inc., Quest Diagnostics Incorporated, and Illumina Inc. These companies operate within the genetic testing and diagnostics industry, offering similar products and services. However, Genetic Technologies Ltd distinguishes itself by leveraging its innovative technology and expertise to provide unique solutions in the field of genetic testing. As a leading player in this market, Genetic Technologies Ltd continuously strives to maintain its competitive edge through research and development, strategic partnerships, and expanding its product portfolio to cater to the growing demands and challenges of the industry.

In which industries is Genetic Technologies primarily active?

Genetic Technologies Ltd is primarily active in the biotechnology and healthcare industries.

What is the business model of Genetic Technologies?

The business model of Genetic Technologies Ltd revolves around genetic analysis and testing services. The company specializes in developing and commercializing genetic risk assessment tools for various diseases and conditions. Genetic Technologies uses advanced genetic screening and analysis techniques to assess an individual's predisposition or susceptibility to certain diseases, thereby aiding in personalized healthcare and preventive medicine. By leveraging its proprietary technologies and intellectual property, Genetic Technologies aims to provide valuable genetic insights and solutions to healthcare providers, insurance companies, and individuals worldwide.

What is the P/E ratio of Genetic Technologies 2024?

The P/E ratio cannot be calculated for Genetic Technologies at the moment.

What is the P/S ratio of Genetic Technologies 2024?

The P/S cannot be calculated for Genetic Technologies currently.

What is the AlleAktien quality score of Genetic Technologies?

The AlleAktien quality score for Genetic Technologies is 6/10.

What is the revenue of Genetic Technologies 2024?

The revenue cannot currently be calculated for Genetic Technologies.

How high is the profit of Genetic Technologies 2024?

The profit cannot currently be calculated for Genetic Technologies.

What is the business model of Genetic Technologies

Genetic Technologies Ltd is an international company specializing in the development of genetic tests and diagnostic kits. It was founded in 1989 and is headquartered in Melbourne, Australia. The company has become a leading provider in personalized medicine and genetic analysis. They offer a wide range of genetic tests for various conditions such as cancer, cardiovascular diseases, osteoporosis, and neurological disorders. They also provide diagnostic kits that are easy to use and provide quick results, making the treatment process easier for patients. Additionally, they engage in research and development to expand their portfolio of medical solutions. The company holds patents in the field of genetic analysis and licenses its technologies to other organizations. Some of their products include BRCA tests for identifying genetic mutations associated with breast and ovarian cancer, BREVAGenplus for assessing an individual's risk of developing breast cancer, CardioID for determining a person's risk of cardiovascular diseases, and COVID-19 tests for diagnosing coronavirus infections. With their innovative solutions in personalized medicine and genetic analysis, Genetic Technologies Ltd continuously expands its existing business areas and actively seeks new opportunities.

What is the Genetic Technologies dividend?

Genetic Technologies pays a dividend of 0 AUD distributed over payouts per year.

How often does Genetic Technologies pay dividends?

The dividend cannot currently be calculated for Genetic Technologies or the company does not pay out a dividend.

What is the Genetic Technologies ISIN?

The ISIN of Genetic Technologies is AU000000GTG7.

What is the Genetic Technologies WKN?

The WKN of Genetic Technologies is 893882.

What is the Genetic Technologies ticker?

The ticker of Genetic Technologies is GTG.AX.

How much dividend does Genetic Technologies pay?

Over the past 12 months, Genetic Technologies paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Genetic Technologies is expected to pay a dividend of 0 AUD.

What is the dividend yield of Genetic Technologies?

The current dividend yield of Genetic Technologies is .

When does Genetic Technologies pay dividends?

Genetic Technologies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Genetic Technologies?

Genetic Technologies paid dividends every year for the past 0 years.

What is the dividend of Genetic Technologies?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Genetic Technologies located?

Genetic Technologies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Genetic Technologies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Genetic Technologies from 9/7/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 9/7/2024.

When did Genetic Technologies pay the last dividend?

The last dividend was paid out on 9/7/2024.

What was the dividend of Genetic Technologies in the year 2023?

In the year 2023, Genetic Technologies distributed 0 AUD as dividends.

In which currency does Genetic Technologies pay out the dividend?

The dividends of Genetic Technologies are distributed in AUD.

All fundamentals about Genetic Technologies

Our stock analysis for Genetic Technologies Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Genetic Technologies Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.